Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
R-CHOP
100%
B-cell Lymphoma 2 (Bcl-2)
40%
Prednisone
20%
Clinical Outcomes
20%
Molecular Subset
20%
Failure Rate
20%
Overexpression
20%
Relapsed or Refractory
20%
Older Patients
20%
Chemotherapy
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Lymphoma
20%
Prognostic Utility
20%
New Therapies
20%
Effective Strategies
20%
Rituximab
20%
Activated B Cells
20%
Targeted Agents
20%
Novel Agents
20%
Central Nervous System Involvement
20%
Clinical Research
20%
Treatment Failure
20%
Predictive Utility
20%
Doxorubicin
20%
Cure Rate
20%
Cyclophosphamide
20%
New Biomarkers
20%
Tool Development
20%
Unmet Needs
20%
Double-hit Lymphoma
20%
Molecular Subtypes
20%
Dual Protein
20%
Chemoimmunotherapy
20%
Refractory Diffuse Large B-cell Lymphoma
20%
Personalization Strategy
20%
Biological Subtypes
20%
Differential Benefits
20%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Biological Marker
16%
B Cell
16%
Disease
16%
Clinical Research
16%
Rituximab
16%
Autologous Stem Cell Transplantation
16%
Central Nervous System
16%
High Risk Population
16%
Doxorubicin
16%
Cyclophosphamide
16%
Prednisone
16%
Vincristine
16%
Biopsy Technique
16%
Chemoimmunotherapy
16%
Chemotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Disease
16%
Prednisone
16%
Biological Marker
16%
Chemotherapy
16%
Rituximab
16%
Clinical Research
16%
Doxorubicin
16%
Cyclophosphamide
16%
Vincristine
16%